A meta-analysis to determine the efficacy and safety of tocilizumab in neuromyelitis optica spectrum disorders.

•First, tocilizumab significantly decreased the ARR ratio and relapse rate of NMOSD.•Second, tocilizumab therapy is safe for patients with NMOSD.•Third, the study found that tocilizumab therapy did not have a significant effect on EDSS score. Larger sample size and long duration of treatments are expected to assess effect on EDSS score in future.